More reads
- Biotech venture capitalists form a lobbying coalition to join the drug pricing debate. (STAT Plus)
- Many generic drugs haven’t hit market, hindering cost-control efforts. (Wall Street Journal)
- Myovant stock rockets on news of positive trial of prostate cancer treatment. (MarketWatch)
.png)
No hay comentarios:
Publicar un comentario